Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02809976 · ClinicalTrials.gov registry record · Phase 2
Topical Ruxolitinib for the Treatment of Vitiligo
A Phase 2 study, sponsored by Tufts Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT02809976 is a Phase 2 study that has completed, run by Tufts Medical Center. The registered enrollment target is 11 participants.
The verdict
NCT02809976, a Phase 2 study, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if topical ruxolitinib 1.5% will provide repigmentation in vitiligo lesions.
Interventions
- DRUG Ruxolitinib 1.5% Phosphate Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02809976
The ClinicalTrials.gov registry entry for NCT02809976 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ruxolitinib 1.5% Phosphate Cream is the first listed.
NCT02809976 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02809976 about?
NCT02809976 is a clinical study titled "Topical Ruxolitinib for the Treatment of Vitiligo". The purpose of this study is to determine if topical ruxolitinib 1.5% will provide repigmentation in vitiligo lesions.
What is the current status of trial NCT02809976?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2016-01. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02809976?
The interventions under investigation include: Ruxolitinib 1.5% Phosphate Cream (DRUG).
Who is sponsoring clinical trial NCT02809976?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.